Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported RSU vesting, a new RSU grant, and a small share sale. On March 4, 2026, he exercised 23,251 restricted share units into the same number of ordinary shares at $0.00 per share and received a new award of 50,643 restricted share units.
He then sold 11,277 ordinary shares at a weighted average price of $32.4645 per share in an open-market transaction effected under a Rule 10b5-1 trading plan, with the footnotes stating this sale was to cover tax withholding from the RSU vesting. After these transactions, he directly held 97,590 ordinary shares and 50,643 restricted share units, each RSU representing a contingent right to one ordinary share or its cash value at settlement.
Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.
Teva Pharmaceutical Industries EVP U.S. Commercial Christine Fox reported RSU vesting, a new RSU grant, and a related share sale. On March 4, 2026 she acquired 20,461 ordinary shares through the exercise of restricted share units and received a grant of 50,643 restricted share units. She then sold 9,098 ordinary shares at a weighted average price of $32.4645 pursuant to a Rule 10b5-1 trading plan, with the sale representing shares required to cover tax withholding from the RSU vesting, leaving her with 75,010 ordinary shares held directly.
Teva Pharmaceutical Industries’ interim Chief Legal Officer, Brian Savage, reported several equity compensation transactions in Teva ordinary shares and restricted share units on March 4, 2026. He acquired ordinary shares through the vesting and exercise of restricted share units and also received a new restricted share unit award.
On that date he acquired ordinary shares via derivative exercises totaling 4,744 shares and 3,466 shares, and was granted 11,280 restricted share units, each representing a right to one ordinary share or its cash value at settlement. To satisfy tax withholding obligations from these vestings, he sold 1,489 shares and 1,186 shares in open-market transactions at a weighted average price of $32.4645 per share. After these transactions, he directly owned 8,461 ordinary shares.
Teva Pharmaceutical Industries’ Chief Accounting Officer, Amir Weiss, reported equity-based compensation activity on March 4, 2026. He exercised previously granted restricted share units (RSUs), converting 10,679 RSUs from a 2022 grant and 5,650 RSUs from a 2024 grant into the same number of ordinary shares at no cash cost.
Weiss also received a new award of 11,280 RSUs granted on March 4, 2026, scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030. Following these transactions, he directly owned 27,158 ordinary shares and 11,280 RSUs, reflecting increased equity exposure with no reported share sales.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting the sale of 17,295 ordinary shares under Rule 144. The filing references a Restricted Share Unit award vesting dated 03/05/2025 and lists 03/05/2026 and the NYSE in the securities table.
Teva Pharmaceutical Industries Limited filed a Form 144 reporting the proposed sale of 14,150 ordinary shares with an aggregate market value of $448,107.86. The shares are tied to a Restricted Share Unit Award with vesting/acquisition noted 03/05/2025, and the filing shows a transaction date of 03/05/2026, handled through Citigroup Global Markets.
Brian Savage reports proposed sales of Teva ordinary shares and an upcoming RSU vesting. The filing lists three dispositions: 450 shares on 01/30/2026 for $15,178.95, 1,000 shares on 12/12/2025 for $29,910.70, and 1,274 shares on 03/03/2026 for $41,226.51.
The notice also shows 3,580 restricted share units vesting on 03/05/2026 described as a compensation award.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed and recent ordinary share activity. The filing lists 17,819 ordinary shares tied to a restricted share unit award vesting on 03/05/2026 through Citigroup Global Markets Inc. It also reports 9,908 ordinary shares sold on 03/04/2026 for $321,658.26.
Teva Pharmaceutical Industries Ltd. insider Richard Francis reported sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05, 442,935 shares on 03/03/2026 for $14,333,332.31, and 23,393 shares on 03/04/2026 for $759,442.05.
The filing also shows a Restricted Share Unit award vesting of 42,452 ordinary shares on 03/05/2026 reported as compensation.